礼来公司正积极洽谈以10亿美元收购Ventyx Biosciences，以加强其在关键疾病领域的研发管道。 Eli Lilly is in advanced talks to acquire Ventyx Biosciences for $1 billion, boosting its pipeline in key disease areas.

2026年1月6日，Ventyx Biosciences股价上涨5.2%，至8.23美元，华尔街日报报道称礼来公司正积极洽谈收购该公司，金额约为10亿美元。 Ventyx Biosciences shares jumped 5.2% to $8.23 on January 6, 2026, after a Wall Street Journal report said Eli Lilly is in advanced talks to acquire the company for about $1 billion. 可能很快将宣布的潜在交易将增加Eli Lilly在炎症、与肥胖有关的心血管疾病和神经退化性疾病方面的输油管。 The potential deal, which could be announced soon, would boost Eli Lilly’s pipeline in inflammatory diseases, obesity-related cardiovascular conditions, and neurodegenerative disorders. Ventyx的股价在过去一年内增长了三倍多，公司正在开发针对克罗恩病、类风湿关节炎及其他疾病的口服治疗药物。 Ventyx’s stock has more than tripled in the past year, and the company is developing oral treatments for Crohn’s disease, rheumatoid arthritis, and other conditions. Eli Lilly的股份在同一天上升了2. 1%, 与另外合作发展口服肥胖症治疗的消息同时发生。 Eli Lilly’s shares rose 2.1% on the same day, coinciding with news of a separate partnership to develop oral obesity treatments. 这两家公司都没有确认该收购。 Neither company has confirmed the acquisition.